Lack of Herpes Simplex Virus (HSV) vaccine, low vaccination rates of Influenza viruses, waning immunity and viral transmission after vaccination underscore the need to reduce viral loads at their transmission sites. Oral virus transmission is several orders of magnitude higher than nasal transmission. Therefore, in this study, we evaluated neutralization of viruses using a natural viral trap protein (FRIL) formulated in clinical-grade chewing gum. FRIL is highly stable in the lablab bean powder (683 days) and in chewing gum (790 days), and fully functional (794 days) when stored at ambient temperature. They passed the bioburden test with no aerobic bacteria, yeasts/molds, with minimal moisture content (1.28-5.9%). Bean gum extracts trapped HSV-1/HSV-2 75-94% in a dose-dependent manner through virus self-aggregation. Mastication simulator released >50% release of FRIL within 15 minutes of chewing the bean gum. In plaque reduction assays, >95% neutralization of H1N1 and H3N2 required ∼40mg/mL, HSV-1 160mg/mL, and HSV-2 74 mg/mL of bean gum for 1,000 copies/mL virus particles. Therefore, a 2000 mg bean gum tablet has more than adequate potency for clinical evaluation and is safe with no detectable levels of glycosides. These observations augur well for evaluating bean gum in human clinical studies to minimize virus infection/transmission.

中文翻译：

---

通过在临床级口香糖中配制的广谱抗病毒蛋白对流感和单纯疱疹病毒株进行减瘤。


缺乏单纯疱疹病毒 （HSV） 疫苗、流感病毒疫苗接种率低、免疫力减弱以及接种疫苗后病毒传播，都强调了减少其传播地点病毒载量的必要性。口腔病毒传播比鼻传播高几个数量级。因此，在这项研究中，我们评估了使用临床级口香糖中配制的天然病毒捕获蛋白 （FRIL） 对病毒的中和作用。FRIL 在 lablab 豆粉（683 天）和口香糖（790 天）中高度稳定，在环境温度下储存时功能齐全（794 天）。他们通过了生物负荷测试，没有好氧细菌、酵母菌/霉菌，水分含量最低 （1.28-5.9%）。豆胶提取物通过病毒自聚集以剂量依赖性方式捕获 HSV-1/HSV-2 75-94%。咀嚼模拟器在咀嚼豆胶后 15 分钟内释放 >50% 的 FRIL 释放。在噬菌斑减少试验中，1,000 拷贝/mL 病毒颗粒需要 ∼40mg/mL、HSV-1 160mg/mL 和 HSV-2 74 mg/mL 的豆胶才能中和 H3N2 的 >95%。因此，2000 毫克的豆胶片剂具有足够的临床评估效力，并且在没有可检测的糖苷水平的情况下是安全的。这些观察结果预示着在人类临床研究中评估豆胶以最大限度地减少病毒感染/传播。